Related Experiment Videos
Octreotide scintigraphy in the head and neck
A Bustillo1, F Telischi, D Weed
1Departments of Otolaryngology-Head and Neck Surgery, University of Miami School of Medicine, Miami, Florida 33101, USA.
The Laryngoscope
|April 20, 2004
Summary
Octreotide scintigraphy (OS) is a reliable diagnostic tool for head and neck neuroendocrine tumors (NET), particularly paragangliomas (PG). This imaging technique shows high sensitivity and specificity in detecting primary and metastatic NET disease.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Neuroendocrine tumors (NET) of the head and neck express somatostatin type 2 receptors (SSR 2).
- Octreotide scintigraphy (OS) utilizes a somatostatin analogue to image NET expressing SSR 2.
- Paragangliomas (PG) are a common type of head and neck NET with high SSR 2 density.
Purpose of the Study:
- To evaluate the diagnostic utility of Octreotide scintigraphy (OS) in head and neck neuroendocrine tumors (NET).
- To assess the reliability of OS in detecting paragangliomas (PG) and other head and neck NETs.
Main Methods:
- Retrospective study comparing OS results with histopathologic diagnosis.
- Involved 74 patients with suspected or confirmed head and neck NETs.
- Focused on sensitivity and specificity for PG detection.
Main Results:
- OS demonstrated 97% sensitivity and 82% specificity for detecting paragangliomas (PG).
- Accurately identified metastases in medullary thyroid carcinoma (MTC) and Merkel cell carcinoma (MCC).
- Detected locoregional recurrences in esthesioneuroblastoma.
Conclusions:
- Octreotide scintigraphy (OS) is a reliable imaging test for head and neck paragangliomas (PG).
- OS can aid in diagnosing primary and metastatic neuroendocrine tumors (NET) in the head and neck region.